Background. De¯uorination of sevo¯urane is catalysed by the hepatic enzyme cytochrome P450 2E1 (CYP2E1). Data about the ontogenesis (developmental variations in activity) of this enzyme suggest a low metabolism of sevo¯urane during the ®rst months of life.
1
Sevo¯urane 2±5% undergoes hepatic biotransformation to inorganic¯uorides and hexa¯uoroisopropanol (HFIP). 2 Fluorides peak in the plasma within 30 min of the end of sevo¯urane administration and are eliminated in the urine. 3 Cytochrome P450 2E1 (CYP2E1) is the major liver enzyme catalysing de¯uorination of sevo¯urane, 4 and accounts in adults for 1±10% of total hepatic CYP proteins. 5 However, its activity is very low during the neonatal period, increasing during the ®rst hour after birth and then gradually increases during the ®rst year of life to reach the adult value in children aged 1±10 yr. 6 The data suggest a lower rate of de¯uorination of sevo¯urane would occur in small children than in adults.
This study was undertaken to explore the effect of age on the metabolism of sevo¯urane in small children, by measuring the postoperative¯uoride urinary excretion.
Methods
After institutional human investigation committee approval and informed parental consent, 45 (11 female/34 male) children ASA physical status I or II, less than 48 months of age undergoing anaesthesia by inhalation of sevo¯urane during elective surgery, were enrolled in this prospective, open, non-randomized clinical trial. Children with impairment of hepatic, cardiac or renal function, or those receiving propofol during induction or maintenance, were not included in the study. Children older than 5 months were given oral or rectal midazolam 0.3 mg kg ±1 , 20 min before anaesthesia that was induced by inhalation of sevo¯urane 7% in nitrous oxide/oxygen (FI O 2 =0.5). After i.v. catheter-ization, dextrose 1% isotonic sodium chloride was infused peroperatively at 25 ml kg ±1 during the ®rst hour, then 83 ml h ±1 m ±2 . The airway was managed with a laryngeal mask or tracheal tube as indicated by the surgery. No neuromuscular blocking agent was administered. Sevo¯urane administration was adjusted as clinically indicated. Immediately after induction of anaesthesia, i.v. acetaminophen 30 mg kg ±1 was administered and followed by 15 mg kg ±1 orally every 6 h. Intra-operative analgesia was given intravenously or by regional anaesthesia performed before the surgical incision. was used. Dextrose 5% infusion (83 ml h ±1 m ±2 ) with electrolytes was used postoperatively until the patient was able to eat normally.
The bladder was emptied after induction of anaesthesia by manual abdominal pressure. If a urinary catheter was not required, a bag was stuck on the skin for urinary collection during the ®rst 24 h after the beginning of sevo¯urane anaesthesia. The child was only included in the study at the time of the urine collection if no urine leakage was observed during this period. It was necessary to screen 70 children before de®nitively including 45 patients in the study because of urine leakage during the 24-h urine collection.
After mixing and measuring the 24-h urine collection, a sample was frozen at ±20°C until measurement of¯uoride concentration. The¯uoride urine concentrations were determined with an ion-selective electrode. 7 Its performance was checked by an Interlaboratory Control program, managed by the Canadian toxicologic centre in Quebec (CHUQ, Sainte-Foy). The intra-essay coef®cient of variation was 1.24, 0.21 and 0.48% for¯uoride concentrations of 13, 53, and 133 mM, respectively. The inter-essay coef®cient of variation was 4 and 4.2% for¯uoride concentrations of 64 and 223 mM, respectively.
The ISM was calculated using the urinary¯uoride excretion during the ®rst 24 h, the exposure to sevo¯urane, and the body surface area, as follows:
with F being urine¯uoride concentration (mm litre ±1 ), U being 24-h urine volume (litre), E being exposure to sevo¯urane (% min), and S being body surface area (m 2 ) [calculated using (4W+7)/(W+90), where W is weight (kg)].
The exposure to sevo¯urane (E) was estimated by the sum of the expiratory sevo¯urane concentrations that were measured every minute during sevo¯urane administration. Measurements were made using an infra-red based, multigas module (SAM module, Marquette electronicsÔ, Milwaukee, USA) and sidestream sampling with a¯ow rate of 250 ml min ±1 . Rise time (delay before automatic return to zero to avoid contamination of measurement by Table 1 Physical characteristics of the patients. Results are medians (interquartile range 25±75%). BSA, body surface area. Exposure corresponds to the sum of expiratory sevo¯urane concentrations measured every minute during anaesthesia. ISM was calculated as indicated in the data analysis section. Comparison between groups by Kruskal±Wallis analysis: compared with group A: *P<0.05, **P<0.01, ***P<0.001; compared with group E: previous sampling) was less than 600 ms and the accuracy equal to 5% of the reading. Data are expressed as medians (interquartile range 25±75%). The ISM were compared in ®ve groups of children (A, <4 months of age; B, 4 to <8 months; C, 8±12 months; D, >12±24 months; and E, >24 months) using Kruskal±Wallis analysis of variance. P<0.05 was considered statistically signi®cant. If P was signi®cant, Kruskal±Wallis analysis was followed by a Dunn's multiple comparison test.
Statistical analysis was performed on the Statview â 4.5 software (Abacus Concepts Inc., Berkeley, CA, USA). A relation between the median values of ISM and the age of each group was searched for by non-linear regression analysis using Prism, version 3.02 (Graph Pad software Inc.).
Results
The physical characteristics of the patients are given in Table 1 . No signi®cant differences between groups in exposure to sevo¯urane (duration of anaesthesia, real cumulative exposure, or MAC hour exposure) were found ( Table 1 ). Median expiratory concentration was 2.3 (1.9±2.7)%. Fluoride urine 24 h concentrations and ISM varied in the ®ve groups: the younger the children, the lower the ISM values. Individual data for ISM are shown in Figure 1 . The relationship between age and ISM was best predicted by non-linear manipulation. The plot of median ISM as a function of the median age for each group, showed an exponential increase in ISM with age, with a curve linearity suggesting an allometric model (i.e. a linear relation between ISM and age after double logarithmic transformation) (Fig. 2) . To con®rm this hypothesis, median and individual values of age and ISM were normalized by double logarithmic transformation. Thereafter, median values of ISM and age were highly correlated by linear regression analysis (R 2 0.98). The plot of individual data of ISM and age after allometric transformation (Fig. 3 ) also showed a linear relationship, despite a lower correlation coef®cient, that was explained by the interindividual variability.
Discussion
The natural log relationship of¯uoride urinary excretion to age after sevo¯urane anaesthesia in small children, suggests an allometric evolution of the metabolism of sevo¯urane during the three ®rst years of life, characterized by a low sevo¯urane metabolism during the ®rst 3 months, followed by an increase in the rate of de¯uorination until 10 months of age. Allometry is used to describe the change in relative size of two physiological variables during growth or evolution. 8 It is frequently observed in the evolution of an organism's morphology and means that the variations during development of physiological variables are linearly related only after double logarithmic transformation. Such a relationship between ISM and age suggests that sevo¯urane metabolism parallels postnatal development of CYPE21.
Data concerning the metabolism of sevo¯urane in children are limited to two previous studies. 3 9 Those ®ndings were correlated with our study: they have, respectively, shown smaller plasma¯uoride peaks between 1 and 6 months, 3 and a lower area under the curve of plasmā uoride in children aged from 1 to 12 yr, 9 than in adults. Fluoride production is related both to the administered dose of sevo¯urane and to the CYP2E1 level activity. 10 Fluoride urinary excretion probably re¯ects more accurately the¯uoride production than plasma concentrations, and has been used to demonstrate the role of CYP2E1 in the hepatic biotransformation of sevo¯urane. 11 However, the use of urinary excretion standardized to sevo¯urane exposure and body surface area in this study is original and has not been validated previously. The concept was guided by the need to take into account both variable exposures to sevo¯urane, and physiological variables that are better indexed to body surface area than to body weight.
A limitation of our conclusion is the existence of extrahepatic metabolism of sevo¯urane, 12 explained by the expression of CYP2E1 in the lung, small intestine, and brain, albeit to a lesser extent than in the liver. 5 In human hepatic microsomes, the rate of de¯uorination of sevo¯ur-ane has been shown to be well-correlated with liver CYP2E1 activity and selective inhibition. 4 One of the clinical implications of the present study is that sevo¯urane is the ®rst substrate of CYP2E1 that could be used as an in vivo probe of its activity in children. Until now, chlorzoxazone, a centrally acting neuromuscular blocking agent, remained the only in vivo probe for CYP2E1 phenotyping in adults. 13 Because of the absence of pharmacological data, its safety in childhood has not been established. Several factors regulate CYP2E1 activity. Developmental expression is one of the keys factors. CYP2E1 is absent or barely detectable in the fetal liver, developing post-natally. Ontogenesis relates to the developmental variation in enzyme activity during growth. Knowledge of the ontogenesis of CYP2E1 resulted from in vitro studies using post-mortem liver samples from children of varying postnatal age. 6 Further implications of the immature metabolism of sevo¯urane in infants and small children relate to nephrotoxicity from¯uoride production.
More than 100 speci®c exogenous substrates of CYP2E1 have been identi®ed, in addition to a number of endogenous ones. 5 14 Low CYP2E1 activity could be protection against the toxicity of drugs or compounds that undergo activation by CYP2E1 to produce metabolites that are cytotoxic or genotoxic, such as halothane and acetaminophen. Oxidative hepatic metabolism of halothane by CYP2E1 mediates an immune-based fulminant hepatic necrosis, because of the production of a reactive tri¯uoroacetyl halide. 15 The lower incidence of this rare but fatal side-effect in children, 16 rather than in adults, could be explained by a lower CYP2E1 activity. The toxicity of acetaminophen is related to its transformation by CYP2E1 in presence of overdose or hepatic gluthation depletion, to a toxic metabolite identi®ed as N-acetyl-p-benzoquinone imine. 17 In mice, this toxicity is delayed, if expression of the CYP2E1 is lacking. 18 Pretreatment by propylene glycol, that inhibits CYP2E1, also prevents hepatic necrosis. 17 It is generally accepted that children are less susceptible than adults to acetaminophen toxicity because of developmental differences in its metabolism. 19 One of these differences could be a lower CYP2E1 activity.
In conclusion, the allometric variation of¯uoride excretion after sevo¯urane anaesthesia during the ®rst years of life, con®rms previous in vitro data about CYP2E1 ontogenesis.
